Document 3eB0eKOmpN49QyZBn4QLDZZvJ

CHEMICAL MARKETING REPORTER 7/2/79 FDA Urges No Change in Reserpine; Will Lower Some Tolerances for PCB I No changes should be made In el ther the labeling or the marketing of the drug reserpine, an advisory panel ! of the Food 4t Drug Administration hat concluded. The panel's recommenda tions received the unanimous support of Us members. National Cancer Institute findings on reeerpine had suggested that the drag, used against Mgh Mood pressure;- might be car cinogenic. The suggestion came from studies of the drug administered to rodents. According to the FDA panel, however, the animal data hod not been adequately analyzed In order to reach such a condo sion linking the medication to a cancer risk. Moreover, Clba-CMgy Corporation,-------facturer of reserpine, has also -t-"rnpl the pathologists' review of the animal data as to Its adequacy. In addition, the panel did not see strong evidence in the epidemiological data that would establish a link between nmpbn usage and breast cancer. FDA aba said last week that It was tow ering the triersncoo be pslyrbisrtnatod bi phenyls In fish, poultry and dairy products. The agency said that new evidence indi cates that POB's ate mere toule than previ ously thought. In particular, recent studies have linked 1 the chemicals to liver tumors and ispew decthre problems in test animals, FDA sold. The impact of FDA's action is exported to fall particularly bard an commercial mult la ilea, of WiaMkiawertkif flak, aw, virtually all fmmratar tprlii , Datails or tha chanfr, In tkt lahranta, appear In Dm Juan at PMrra/ JUftiUr The new tslerancaa, which are la the law MTU-per-mllllon ranpe. are la became at nctlve on product, ihlpped la latantale commerce on Aumat ** I HONS 008914